Receptor tyrosine kinase alterations in AML - biology and therapy

DOI: 10.1007/978-0-387-69259-3_6
Cancer Treatment and Research, 2010, 145, 85-108.

#	Paper	IF	Citations
10	CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia. *Japanese Journal of Clinical Oncology*, **2010**, 40, 1046-52	2.8	18
9	Heme controls the regulation of protein tyrosine kinases Jak2 and Src. *Biochemical and Biophysical Research Communications*, **2010**, 403, 30-5	3.4	35
8	Mechanisms of acquired resistance to tyrosine kinase inhibitors. *Acta Pharmaceutica Sinica B*, **2011**, 1, 197-207	15.5	56
7	Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. *Medical Oncology*, **2011**, 28 Suppl 1, S483-9	3.7	31
6	Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. *Leukemia Research*, **2013**, 37, 1461-7	2.7	27
5	Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target?. *Veterinary Immunology and Immunopathology*, **2013**, 152, 325-32	2	5
4	Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. *Clinical Biochemistry*, **2013**, 46, 49-53	3.5	52
3	Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. *Biomaterials*, **2015**, 67, 42-51	15.6	64
2	Epigenetic and Genetic Alterations in Leukemia. **2021**, 3-23		
1	The Research Advances of Aptamers in Hematologic Malignancies. **2023**, 15, 300		0